Mentorship in research on opioid use disorder, HIV and marginalized populations

阿片类药物使用障碍、艾滋病毒和边缘化人群研究中的导师 注射毒品的人(PWID)服用过量药物和增加艾滋病毒风险的风险很高，但他们的情况并不理想 接受基于证据的阿片使用障碍(OUD)治疗和艾滋病毒预防措施。接合PWID 而来自边缘群体的自闭症患者需要创新的方法。Aaron D.Fox医学博士是一位 艾伯特·爱因斯坦医学院上瘾医学内科医生兼副教授- 蒙特菲奥里医疗中心。他是一位经验丰富的研究导师，布朗克斯过渡诊所的主任， 它为以前被监禁的人提供了医疗之家，也是两名 创新丁丙诺啡治疗干预措施的临床试验(见下文)。爱因斯坦-蒙特菲奥里研究所 临床和转化研究，以及爱因斯坦-洛克菲勒-纽约州立大学艾滋病研究中心，提供了 支持早期调查人员和受训人员的良好环境。作为美国国立卫生研究院治疗计划的一部分 最近，爱因斯坦-蒙特菲奥雷获得了IMPOWR发展研究中心的四项赠款之一 关于慢性疼痛和OUD。在这个K24职业中期导师奖中，福克斯博士建议利用这些 指导六名有才华的早期研究人员从事艾滋病、艾滋病毒和边缘化研究的资源 人口。福克斯博士还将在指导、新的研究方法和药物政策领导方面获得技能 具有以下职业发展目标：1)为不同的早期阶段提供出色的指导 将在艾滋病治疗和艾滋病毒预防方面发展独立研究事业的研究人员；2)获得 具备通过互联网进行艾滋病毒预防研究的技能；以及3)将证据转化为临床指南和 关于获得成瘾治疗和艾滋病毒预防服务的政策。为了实现这些目标，福克斯博士 将召集一个在指导、互联网中介研究和药物政策方面具有专业知识的顾问团队，同时 参加专门针对研究、指导和卫生政策领导力的培训。福克斯博士目前的研究 提供一个独特的环境，使早期研究人员能够参与以患者为中心的研究 初级保健、医院、注射器服务项目，以及监禁后的“过渡诊所”。福克斯博士领衔 两项大型随机对照试验：丁丙诺啡微剂量诱导治疗慢性阻塞性肺疾病住院患者 慢性疼痛(RM1DA055437)和丁丙诺啡的有效性、安全性和成本效益 在注射器服务计划中开始治疗(R01DA044878)。该应用程序还提出了新的互联网- 与第一个正式的基于互联网的邮件Next Divio合作进行中介艾滋病毒预防研究 美国的分娩注射器服务计划。这些研究将为受训人员提供一个平台 发展与药物政策和临床指南高度相关的以患者为中心的研究。 拟议的K24奖项的完成将促进我们在治疗和艾滋病毒预防方面的研究，同时 还扩大和多样化了致力于OUD、艾滋病毒和边缘化人口的研究队伍。

Mentorship in research on opioid use disorder, HIV and marginalized populations People who inject drugs (PWID) are at high risk for overdose and increasing HIV risk, yet they sub-optimally receive evidence-based opioid use disorder (OUD) treatment and HIV prevention measures. Engaging PWID and persons with OUD from marginalized groups requires innovative approaches. Aaron D. Fox, MD MS is an Addiction Medicine physician and Associate Professor of Medicine at Albert Einstein College of Medicine- Montefiore Medical Center. He is an experienced research mentor, the director of the Bronx Transitions Clinic, which provides a medical home to formerly incarcerated individuals, and the principal investigator of two clinical trials of innovative buprenorphine treatment interventions (see below). Einstein-Montefiore’s Institute for Clinical and Translational Research, and the Einstein-Rockefeller-CUNY Center for AIDS Research, provide an outstanding environment for supporting early-stage investigators and trainees. As part of the NIH HEAL initiative, Einstein-Montefiore was recently awarded one of four IMPOWR grants to develop a research center on chronic pain and OUD. In this K24 mid-career mentorship award, Dr. Fox proposes to capitalize upon these resources in mentoring six talented early-stage investigators in research on OUD, HIV, and marginalized populations. Dr. Fox would also gain skills in mentoring, new research methods, and drug policy leadership with the following career development objectives: 1) To provide outstanding mentorship to diverse early-stage investigators who will develop independent research careers in OUD treatment and HIV prevention; 2) To gain skills in internet-mediated HIV prevention research; and 3) To translate evidence into clinical guidelines and policy regarding access to addiction treatment and HIV prevention services. To meet these objectives, Dr. Fox will convene an advisory team with expertise in mentoring, internet-mediated research, and drug policy, while participating in training specific to research mentoring and health policy leadership. Dr. Fox’s current studies provide a unique environment where early-stage investigators can participate in patient-oriented research in primary care, hospitals, syringe services programs, and a post-incarceration “transitions clinic.” Dr. Fox leads two large randomized controlled trials: buprenorphine microdose inductions for hospitalized patients with chronic pain (RM1DA055437), and the effectiveness, safety, and cost-effectiveness of buprenorphine treatment initiation at syringe services programs (R01DA044878). This application also proposes new internet- mediated HIV prevention research in collaboration with NEXT Distro, the first formal internet-based mail delivery syringe services program in the United States. These studies will serve as a platform for trainees to develop careers in patient-oriented research that is highly relevant for drug policy and clinical guidelines. Completion of the proposed K24 award would advance research in OUD treatment and HIV prevention, while also expanding and diversifying the research workforce dedicated to OUD, HIV, and marginalized populations.